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ABSTRACT 
Background 
The podocytes are injured in many acquired glomerular diseases. This may present as 
proteinuria or morphological changes such as foot process effacement (FPE) or loss of 
podocytes in the urine.  The exact mechanisms are still mainly unknown. However, a number of 
proteins identified in the slit diaphragm (SD) of the podocytes, including Dendrin and Neph1, 
are believed to be of significance in the podocytes’ response to injury and in the resulting 
pathophysiological development. Dendrin was primarily found to be associated to the actin 
cytoskeleton in mouse podocytes. Neph1 is a transmembrane protein that together with Nephrin 
forms a complex in the SD, involved in polymerization of the actin cytoskeleton and 
proteinuria. Plekhh2 is an uncharacterized protein that we localized to the podocyte cytoplasm. 
 
Aim 
The principal aim was to study the expression and role of novel structural glomerular proteins in 
acquired human glomerular disease. In the first study, focusing on the expression of Dendrin in 
normal human kidney and in the glomerular disease Minimal Change Nephrotic Syndrome 
(MCNS), light and immune electron microscopy (iEM) was used. In the second study, the 
subcellular localization of the uncharacterized protein Plekhh2 in normal human kidney and Focal 
Segmental Glomerulosclerosis (FSGS) was investigated by immunofluorescence (IFL) and iEM. 
Neph1 and Nephrin were studied in FSGS, MCNS and in the corresponding experimental models 
Adriamycin nephropathy (ADR) and puromycin aminonucleoside nephrosis (PAN). Lastly, we 
returned to Dendrin, and studied the expression in the podocyte nuclei in IgA Nephropathy (IgAN) 
and Membranous Nephropathy (MN) with iEM and analyzed the gene expression with 
microarray.  
 
Results 
Dendrin was localized to the glomerular slit diaphragm (SD). There was no significant change 
in the amount of Dendrin in MCNS compared to controls by IFL and iEM. In areas of FPE 
Dendrin was redistributed from the SD to the podocyte cytoplasm. Plekhh2 was localized 
mainly to the podocyte cytoplasm. The expression was reduced in FSGS. Double staining of 
Neph-1 and Nephrin showed the proteins in close connection in the SD. Neph1 was 
significantly reduced in FSGS, MCNS, ADR and PAN. The reduction of Neph1 was also seen 
in areas without FPE. Nephrin was unchanged in FSGS, but reduced in MCNS and PAN. 
Dendrin was increased in the podocyte nuclei in IgAN, with a corresponding two fold increase 
of the gene expression. Both protein and gene expression of Dendrin was unchanged in MN.  
 
Conclusion 
In preserved slits and in areas without FPE in MCNS, the amounts of Dendrin were unchanged 
compared to controls. The redistribution might therefore be secondary to FPE, per se. However, 
the increase of nuclear Dendrin in IgAN suggests an upregulated apoptotic pathway and a 
possible role for Dendrin in the pathogenesis of this disease. Plekhh2 was reduced and relocated 
from the plasma membrane to centrally in the foot processes in FSGS. Neph1 was reduced in 
FSGS, MCNS, ADR and PAN, in contrast to Nephrin which was unchanged in FSGS. This 
could indicate a disruption of the Neph1-Nephrin complex and an involvement of Neph1 in the 
pathogenesis of this disease.  
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3 LIST OF ABBREVIATIONS 
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GBM= Glomerular Basement Membrane 
 
HSP= Henoch–Schönlein purpura 
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PAS= Periodic-Acid Sciff 
 
PASM= Periodic Acid Silver  
 
SD= Slit Diaphragm 
 
TEM= Transmission Electron Microscopy 
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4 BACKGROUND 
 
 
4.1 THE NORMAL KIDNEY 
 
 
4.1.1 Structure 
 
The normal human kidney measures about 12 cm. Blood from the abdominal aorta 
enters the kidneys via the renal arteries. Structurally the kidney is composed of an outer 
cortex and an inner medulla. The kidneys’ functional units are called nephron. A 
normal human kidney has approximately 1 million nephrons, composed of a 
glomerulus and tubular system (Figure 1). The glomerulus consists of small capillary 
bundles, held together structurally and functionally by mesangial cells and their matrix; 
all encapsulated by Bowmans capsule (Figure 2-4) which is connected to the tubular 
system. 
 
 
 
 
 
Figure 1. Structure of the normal human kidney.  
Copyright © 2007, Rights Managed by Nature Publishing Group. 
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Figure 2.  The glomerular filtration barrier. Copyright © 2009, Rights Managed by Nature Publishing 
Group. 
 
 
 
Figure 3a. Light microscopy image of normal glomeruli. Figure 3b. Light microscopy image of normal 
glomerulus. 
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Figure 4. Electron microscopy image of a normal glomerulus. C= capillaries, M=mesangium. 
 
 
 
 
4.1.2 Function 
 
The kidneys main functions are clearing the blood from waste products and regulating 
the water fluid levels. Blood enters the glomerulus via the afferent (inward) arteriole. 
Filtered blood then leaves the glomerulus through the efferent (outgoing) arteriole. The 
filtration product, the primary urine, is normally free from proteins and blood cells and 
measures about 180 liter/day. Most of this liquid is reabsorbed in the tubular system 
and the amount of urine will be about 1.5 liter / day. 
 
 
 
Figure 5. The blood is filtered through the glomerular capillaries, over the three layers of the filtration 
barrier. The product, the primary urine is collected in the Bowmans capsule before it enters the tubular 
system. Copyright © 2008, American Physiological Society. 
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4.1.3 The glomerular filtration barrier  
 
Three core constituents build up the filtration barrier of the glomerular capillaries: the 
endothelium, the glomerular basement membrane (GBM) and the visceral epithelial 
cells, the podocytes (Figure 2, 5, 6 and 7). Compounds of low molecular weight and 
small size, such as water, urea and glucose readily pass the filtration barrier. Albumin 
and other large proteins ( ≥ 80 KDa) are hindered to prevent macromolecular leakage 
from the blood to the filtrate. The primary urine is collected in the Bowman´s capsule 
before it enters the tubular system for further re-absorption of fluids. 
The first layer, the fenestred endothelium has a negatively charged cell surface 
glycocalyx, containing proteoglycans and sialo proteins. Due to great difficulties to 
culture endothelial cells without shifting their phenotype, they are not very well 
studied in comparison to the other components of the filter. Also, the endothelial layer 
has not been considered essential to the selective glomerular filtration, mainly because 
of its large fenestrae. It is now, however, recognized that the endothelial cell coat has 
charge-selective properties (1, 2) and that the cell is bound non-covalently to the 
surface which means that the layer is much less permeable than previously believed. 
Numerous current studies present data that highlights the endothelium as a perm-
selective layer (1, 3, 4, 5). 
The mayor components of the second layer, the 300-350 nm GBM, are type-ІV  
collagen and β2-laminin, interconnected by nidogen and agrin. The GBM is not 
generally regarded as the main barrier of neither size nor charge selection. This has 
been shown by studies on the selective removal of highly anionic substances, which 
appears to neither influence the glomerular charge selectivity nor increase the degree of 
proteinuria (6).  
The outer wall of the capillaries, facing Bowman´s capsule, consists of podocytes with 
cell bodies and foot processes (Figure 6). Filtration slits, spanned by porous slit 
diaphragms (SD), are located between neighboring foot processes (Figure 6). Both 
podocytes and endothelial cells adhere to the adjacent mesangial extracellular matrix 
(ECM). Through connecting surface receptors the cells and the ECM together regulate 
growth, differentiation and survival (7, 8) of the glomerular components.  
Recently a location between the podocytes and the basement membrane was described. 
This so called sub-podocyte space (SPS) covers approximately two thirds of the 
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basement membrane and allegedly regulates protein transfer to Bowmans space 
through exit pores (9).  
 
 
Figure 6. The epithelial podocytes with foot processes and intermediate slit diaphragms. Copyright, © 
2004 American Society for Clinical Investigation. 
 
 
 
 
 
Figure 7.Electron microscopy image of the glomerular filtration barrier. E= endothelium, GBM= 
glomerular basement membrane, P= podocytes. 
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4.1.4 Filtration  
 
Until recently the general idea was that glomerular filtration is driven by diffusion 
and convection (by the flux of water). It seems, however, as electrokinetic effects are 
involved. Briefly, the ionic plasma fluid interacts with the charged filter walls when 
passing the glomerular filter. Menzel et al (10) calculated the sum of these 
interactions. The fact that anions pass the glomerular filter slightly faster than cations, 
generate an electrical potential across the filter, directly proportional to filtration 
pressures. 
A pronounced mystery of the glomerular filtration is that despite the fact that more 
than 99.9% of the 7 kg plasma proteins filtered every day is retained by the filter, the 
filter is never clogged. This has led to the hypothesis that most plasma proteins are 
excluded from the filtrate before it reaches the SD. 
Numerous mechanisms have been proposed, as summarized  by Haraldsson et al (1, 2), 
including: ingestion of proteins by mesangial cells, GBM charge repulsion, a 
hypothesis governing gel infusion and endocytotic transport of albumin to the 
podocytic cytoplasm and excretion in Bowmans space (11). 
In 2011 Menzel et al (10) suggested that the energy potential derived from albumin 
and most plasma proteins negative charge will induce an electrophoretic flux, toward 
the blood, which will transport these macromolecules from the filter back into the 
blood. Positively charged components will in turn, be transported from the filter into 
the urine by diffusion, convection, and electrophoresis. The required energy is 
supplied by the blood pressure. The podocytes main function in the filtration process 
would thus, based on this hypothesis, be as generators of a potential difference.  
 
 
 
4.1.5 The podocyte 
 
Podocytes are allegedly terminally differentiated cells. They can enter the cell cycle but 
has a very limited capacity of complete cell division. It is still not known if and how 
podocytes can be substituted (12). Two mechanisms proposed:  
1. Stem cell migration via the blood from the bone marrow, which has been 
demonstrated in experimental systems (13). 
2. Migration of the parietal epithelial cells layering Bowmans capsule to the glomerular 
tuft, and thereafter a phenotype differentiation (14).   
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The highly specialized podocyte consists of a cell body, major processes, secondary 
processes and foot processes. The cell body, the secondary and major processes are 
constructed primarily of intermediate filaments which maintain the shape, and by 
microtubules which provide the dynamics of the cytoskeleton. The foot processes 
contain long actin filaments that connect adjacent processes, and are anchored to the 
underlying basement membrane through transmembrane receptors, such as integrins, 
tetraspanins and dystroglycans. The integrins are, in turn, linked to the podocyte actin 
cytoskeleton. The cell membrane of the foot processes is divided into three domains: 
the apical membrane domain, the SD and the basal membrane domain (15). The basal 
membrane domain is attached to the GBM and all three domains are linked to the actin 
cytoskeleton. 
The actin ability to swiftly polymerize and de-polymerize allows morphological 
changes of the foot processes. Regulation of the cytoskeletal dynamics is crucial to the 
normal podocyte function.  
The podocytes both retain the structure of GBM and produce many of its components, 
for example heparan sulphate proteoglycans. Damage to the podocytes disturbs this 
symbiosis. A thickening of the GBM due to the podocytes increased production of 
matrix protein is seen in the glomerular disease Membranous Nephropathy (MN). The 
podocytes also affect the endothelial cells by the production of vascular endothelial 
growth factor (VEGF) and angiopoietin, which regulate the fenestration of the 
endothelial cells and is essential for their development (16). 
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Figure 8. Adjacent foot processes and the intermediate slit diaphragm. Copyright © 2009, Oxford 
University Press. 
 
 
4.1.6 The slit diaphragm 
 
Adjacent foot processes interdigitate through 25-60 nm slit diaphragms (SD), 
functioning both as charge and size selective barriers and as platforms connected to the 
intracellular cytoskeleton by signaling pathways (Figure 8 and 9). The morphological 
structure of the SD resembles desmosomes and adherens junctions.The slit diaphragm 
was first described by Karnovsky in 1974 in mice and rats (17) and the following year 
in humans (18). That same year was the SD also reported to be lost in areas of foot 
process effacement in Minimal Change Nephrotic Syndrome (MCNS) and restored 
after steroid treatment (19). In 1998 Tryggvason et al. identified the protein Nephrin as 
a major component of the SD (20). By positional cloning, a mutation in its encoding 
gene, NPHS1, could be linked to congenital nephrosis of the Finish type (20), a 
condition characterized by heavy proteinuria in utero. These findings led to the notion 
that structural changes of the SD and the podocyte cytoskeleton are involved in 
nephrotic diseases. It is now recognized that SD proteins, for example Nephrin (20), 
Neph1 (21), Podocin (22 ), P-cadherin (23), and FAT (24), are linked to the podocyte 
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cytoskeleton through  adaptor proteins (25 ), such as CD2-associated protein (CD2AP) 
(26, 27), Zonula Occludens (ZO)-1 (28), β-catenin, Nck and p130Cas (29) (Figure 8). 
The adaptor proteins, in turn, interact either directly with actin or indirectly through 
actin-binding proteins, such as β-actinin, Synaptopodin, Cofilin or Fimbrin (29).  
The morphological structure, polarity and function of the foot processes are thus 
controlled by the extracellular SDs transmission of signals (30) to the intracellular actin 
cytoskeleton (Figure 9). For example, Podocin and TRPC6 are believed to function as 
sensors of mechanical stress and pressure from filtration, and contribute, through 
signaling cascades, to resulting rearrangements of the cytoskeleton (31, 32). Further, 
phosphorylation of the proteins involved in the signaling pathways of the SD function 
as on/off settings of the podocytic response to external provocations (33).  
New genes of the SD are continuously being identified and associated with human 
proteinuric disease, the latest being; APOLI, PTPRO, COQ26, INF2 and MYO1E (33). 
The exact molecular construction of the SD is to this day unestablished.   
 
 
Figure 9. Signaling pathways at the slit diaphragm.  Copyright © 2013, Rights Managed by Nature 
Publishing Group. 
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4.2 PATHOLOGY 
 
The prevalence of chronic kidney disease (CKD) is approximately 10% globally (34).  
As a consequence of the increased incidence of type 2 diabetes and an ageing 
population, the number is predicted to rise even further the forthcoming years. Chronic 
kidney disease eventually leads to renal failure, requiring dialysis or transplantation. 
Following Diabetic Nephropathy and hypertonia, glomerulonephritis is the most 
common cause of chronic kidney failure, and counts for 25% of the cases (34, 35). 
Due to limited knowledge of the pathogenic mechanisms behind acquired glomerular 
diseases, the therapies offered today are unspecific and sometimes even harmful.  
 
 
4.2.1 Proteinuria and foot process effacement  
 
Urinary protein excretion is considered normal up to 150 mg per day, with albumin 
excretion below 30 mg. When the urinary protein concentration measures ≥3,5 g 
protein/24h it is diagnosed as  proteinuria, - the most common sign of renal disease and 
glomerular dysfunction. Extensive protein leakage is in itself harmful to the kidney 
(36), and also an independent risk factor for cardiovascular mortality (37). Proteinuria 
is caused by the dysfunction of the selective permeability through the filtration barrier, 
or an impairment of the tubular reabsorption, but the molecular mechanisms are not 
known (38). The combination of pronounced proteinuria (>3.5 g protein/24h), 
hypoalbuminuria, oedema and hyperlipidemia is referred to as nephrotic syndrome. 
Several mutations of podocyte associated proteins have been identified in hereditary 
proteinuria, from those related to the slit diaphragm, cell matrix, cytoskeleton and 
podocyte surface, to transcriptional factors, and podocyte-secreted proteins (39). For 
example: CD2AP (25), α-actinin-4 (40), Transient Receptor Potential Channel 6 
(TRPC6) (41), Podocin (42), and most recently Myosin 1E (MYO1E) in childhood-
onset steroid resistant nephrotic syndrome (43). Functional loss of SD-associated 
Nephrin, Podocin and TRCP6 channels has been shown to be involved in the onset of 
proteinuria in acquired glomerular diseases (44).  
However, the maintenance of glomerular function requires working collaboration 
between all present cells, not just podocytes, but also endothelial, mesangial and 
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parietal epithelial cells.  Therefore proteinuria should be considered a defect of the 
filtration barrier as a whole, occurring regardless of which glomerular compartment that 
is injured (1, 16, 45). There are numerous mutations of GBM proteins associated with 
proteinuria, such as collagen type IV and laminin, as well as the endothelial glycocalyx 
association to albuminuria in type 1 diabetes (46).  Furthermore, deficiency of α3β1-
integrins separates the foot processes from the GBM and induces proteinuria (47). 
There are also circulation factors and signaling pathways known to be associated to 
proteinuria: such as angiotensin II, VEGF, calcium (48) and Rho GTPase signaling 
(15).  
 
A characteristic ultrastructural finding in nephrotic syndrome and proteinuric diseases 
is so called foot process effacement (FPE), as first described by Farquar in 1957 (49) 
This re-arrangement of the cytoskeletal parallel actin filaments into a compressed 
network (Figure 10 and 11),  is the podocytes adaptive response to injury or stress (33, 
50). At the initial stage the foot processes retract into short projections, which, at the 
second stage are further withdrawn into the primary podocyte cell processes and 
finally, fuse with the cell bodies. The podocyte cell bodies are by then covering the 
GBM by direct adherence (50).  
 
 
 
 
 
Figure 10. Normal foot processes (left) and effaced foot processes (right). Copyright © 2000, Journal of 
Clinical Investigation. 
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Figure 11a. Electron microscopy image of normal glomerular capillaries. Figure 11b. 
Electron microscopy image of foot process effacement in MCNS. 
 
 
 
 
The glomerular injury resulting in FPE, may be caused by toxins or viruses, metabolic 
diseases (e.g. diabetes), immunological responses/defects, genetic mutations, ischemia 
or abnormal glomerular hemodynamic forces (51, 14). Podocytes with effaced foot 
processes commonly form long apical microvilli which attach to the GBM or to the 
parietal basement membrane (PBM). This act has been described as the podocytes 
pursuit for new attachment sites (50).  
When rapid polymerization of the actin cytoskeleton is required due to damage or 
development, Nephrin is phosphorylated and recruits adaptor protein Nck, which in 
turn activates actin. Neph1 is also known to be phosphorylated in injured glomeruli, 
but the exact signaling pathway remains to be defined (52). The polymerization of the 
actin cytoskeleton is a reversible event, which has been successfully shown in a number 
of animal studies (53) and is also seen in the glomerular disease Minimal Change 
Nephrotic Syndrome (see below) following treatment. Confusingly, the SD shift 
towards tight junction formation, which is seen as a result of FPE, would rather prevent 
proteinuria. Effacement in itself does not seem to be sufficient to cause proteinuria, as 
proteinuria can occur without FPE, and the degree of FPE does not correlate to the 
amount of proteinuria (54, 55).  Although still extensively debated, the general belief is 
currently that proteinuria and FPE are two independent symptoms of glomerular injury. 
Indeed, in 2010 Gagliardini et al (56) closely examined the pores of the SD with 
scanning EM, and could thereby describe them as heteroporous instead of the 
previously proposed zipper-like structure. They also found significantly larger pores in 
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rats with proteinuric pathologic conditions, than in controls. This, they suggested, could 
explain proteinuria with unchanged foot process morphology. 
 An alternative theory governing glomerular filtration and proteinuria is the notion that 
the proximal tubule retrieves proteins that are filtered through the glomerulus by trans-
cytosis, and that defects of this reuptake mechanism are responsible for proteinuria 
(57).  
Kriz and colleagues (50) recently suggested that FPE is the podocytic strategy to escape 
detachment from the GBM, following injury. In order of doing so, the podocytes form a 
temporary basis that enables reconstruction of the filtration barrier when possible.  
Thus, the effacement of the foot processes would also aim to limit protein leakage by 
preventing podocyte detachment. This would imply that measuring urinary podocytes 
would be a far better marker of disease severity and treatment response than 
proteinuria. The authors do acknowledge that many genetically induced disorders and 
some acquired diseases would be excluded from this theory, where the FPE is triggered 
as a result of specific mutations rather than as a response to injury. 
 
 
4.2.2 Podocytopenia and glomerulosclerosis 
 
A significant factor in the progression of proteinuric kidney diseases to kidney failure is 
podocytopenia, the loss of podocytes.  The depletion can either be caused by direct loss 
by apoptosis, necrosis, autophagy or detachment, or by glomerular enlargement 
resulting in indirect podocyte loss (14) (Figure 12). Detachment of podocytes is most 
abundantly preceded by FPE, as the primary reaction to insult (50). 
Based upon the study of rat models, the consequences of different degrees of 
podocytopenia have been recognized (58, 59). If the initial glomerular insult does not 
result in podocyte depletion, the glomerulus may repair and return to normal function. 
Though, following >20% podocyte loss, the glomerular capillary loop adhere to 
Bowmans capsule.  20-40% podocyte loss results in segmental sclerosis and >60% 
leads to a glomerulus with global sclerosis and no filtration function. Proteinuria 
develops correspondingly (58, 59).   
Glomerular enlargement, associated to for example obesity and acromegaly, is another 
contributor to glomerulosclerosis (60).  
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Figure 12. The podocyte depletion theory. Copyright © 2007, Rights Managed by Nature Publishing 
Group. 
 
 
 
4.2.3 Focal Segmental Glomerulosclerosis  
Focal Segmental Glomerulosclerosis (FSGS) is the primary glomerular disorder that 
most commonly result in end stage renal disease in the United States (61). The disease 
manifests with proteinuria, glomerular lesions of focal and segmental sclerosis and FPE 
(Figure 13). In contrast to Minimal Change Nephrotic Syndrome (see below), the 
effacement seen in FSGS is not readily reversed. FSGS can be of either primary or 
secondary type. Secondary FSGS have an underlying cause, such as virus-or drug-
association, heritability or can be mediated by adaptive structural-functional responses, 
such as renal dysplasia or obesity. 
The disease is primarily a histological diagnosis, based on the presence of segmental 
sclerotic lesions involving some, but not all glomeruli. Ever since the first portrayals of 
the disease by Fahr and Rich in 1925 and 1957 respectively, several different types of 
FSGS have been described (62-64) and numerous attempts at classification have been 
made. According to the pathologic classification system of Colombia (65, 66), FSGS 
include five different subclasses based on the presence of histological features; cellular, 
tip lesion, perihilar, collapsing and not otherwise specified (NOS). Based upon this 
classification system, the perihilar type is characterised by sclerosis and/or hyalinosis in 
the perihilar region of the glomerulus. The cellular, tip and collapsing variants must be 
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excluded. The tip lesion variant should have at least one glomerulus with defining 
features of segmental lesion involving the glomerular tip domain and adhesion or 
confluence of glomerular tuft lesion in the tip domain. The lesion may be sclerosis,  
endocapillary hypercellularity or foam cells. In our second study we used the perihilar 
and tip lesion types as these are the most common primary variants of FSGS in our 
region. 
The significance of distinguishing between these histological types of FSGS clinically 
has been debated, but numerous studies (67-69)  have demonstrated considerable 
differences in both clinical features and renal outcome between the histological types. 
As earlier discussed, podocytopenia can lead to sclerosis, but it is not known whether 
all identified mutations in hereditary FSGS, such as α-actinin-4 (40, 70), Podocin (71), 
CD2-associated protein (CD2AP) (72), TRPC6 (73, 74) and Inverted Formin 2 (INF2) 
(75), lead to podocyte loss or target the podocyte structure through other mechanisms. 
Idiopathic, primary FSGS is presently thought to be the result of circulating 
permeability factors, such as soluble urokinase-type plasminogen activator receptor 
(suPAR) (76) and cardiotrophin-like cytokine-1 (CLC-1) (77).       
   
 
  Figure 13. Light microscopy image of FSGS. PAS staining of 
a glomerulus with a segmental sclerosis (Arrow). 
 
 
 
 
4.2.4 Minimal Change Nephrotic Syndrome 
 
Minimal Change Nephrotic Syndrome (MCNS) shares the most prominent clinical 
manifestations with FSGS, such as severe FPE and proteinuria – however, with normal 
appearance in light microscopy, as opposed to the focal, segmental glomerulosclerosis 
that characterizes FSGS. The use of transmission electron microscopy (TEM) to 
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identify FPE is therefore a helpful tool in analyzing biopsy material (Figure 11). 
MCNS is the most common disease underlying nephrotic range proteinuria among 
children. It is typically activated by immunological events, such as allergy.  The 
podocytic injury in MCNS, resulting in the characteristic FPE is thought to be caused 
by a circulating factor secreted by abnormal T cells (78). Treatment with 
glucocorticoids does indeed swiftly restore the normal podocyte shape and glomerular 
function. In 2003, we presented reduced Nephrin expression in the podocytes of MCNS 
patients (79).  
CD80, a transmembrane protein involved in T-cell activation has recently been shown 
to be significantly increased in MCNS compared to FSGS (80). Hopes are that this 
could be the long sought factor distinguishing MCNS from FSGS in a simple urine test. 
Prior to this study there were some discussions regarding the staining of CD80/B7-1 in 
glomerulopathies (81) and whether the results were merely artefacts of cross-reactivity 
(82).  
  
 
 
4.2.5 IgAN nephropathy  
 
IgA nephropathy (IgAN) was first described by Berger and Hinglais in 1968 (83), and 
is the most common primary glomerulonephritis worldwide. The disease is 
immunohistologically defined by the presence lgA deposits, which has been shown to 
be galactose deficient, within the glomerular mesangium (61). Further, mesangial cell 
proliferation and matrix expansion is seen, resulting in a reduction, and eventually 
occlusion, of the capillary lumen and glomerulosclerosis. 
Clinically, IgAN patients may present with hypertension, hematuria with or without 
proteinuria of various degrees (84). The fact that the intensity of the deposits and the 
severity of glomerular injury do not correlate, is extensively studied. The detailed 
immunological mechanism behind glomerular IgA deposits is still unidentified. Some 
therefore believe lgAN to be a collection of different diseases, sharing the deposits but 
not the underlying pathology (85). The degree of glomerulosclerosis seems to correlate 
to podocyte depletion, and IgAN patients along with MN patients (see below), show an 
increase of excreted podocytes in urine (86, 87). Segmental sclerosis in IgAN may be a 
result of healed necrotizing lesions, leaving segmental scars (88). 
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In 2009 the collaboration of the International IgA Nephropathy Network and the Renal 
Pathology Society published two papers describing their new IgAN Oxford 
Classification (89, 90). With the aim to identify specific pathological features 
predicting the progression risk of the disease in individual IgAN cases, they presented 
four variables of independent value: (1) mesangial hypercellularity, (2) segmental 
glomerulosclerosis, (3) endocapillary hypercellularity, and (4) tubular 
atrophy/interstitial fibrosis. However, the prognostic value of the classification system 
has since then been challenged (88, 91- 94). 
 
 
 
4.2.6 IgA vaculitis 
 
IgA vasculitis (IgAV) (formerly known as Henoch Schönlein purpura) is an acute 
immunoglobulin A (IgA)–mediated disorder, mainly affecting children. It is 
characterized by vasculitis involving the small vessels of the skin, the gastrointestinal 
tract, the kidneys and the joints. The renal involvement with IgA deposits in vascular 
walls and/or in glomeruli correlates to the long term prognosis. Clinically, the patients 
show microscopic hematuria and low-grade proteinuria.  The etiology and pathogenesis 
are unknown, but the disease seems to be associated to, and induced by infections, in 
particular of the upper respiratory tract (95). 
 
 
 
4.2.7 Membranous Nephropathy 
 
Membranous Nephropathy (MN) patients typically show proteinuria, edema, 
hypoalbuminemia, and hyperlipidemia. The disease can be of either primary or 
secondary origin, and is the most common idiopathic nephrotic syndrome in white 
adults. Underlying causes of secondary types of MN are autoimmune diseases, 
infection, drugs, and malignancy (96).  30-40% of the patients progress toward end-
stage renal failure within 5 to 15 years (97). 
MN is immunologically mediated and forms glomerular sub-epithelial immune-
complex deposits with subsequent thickening of the glomerular basement membrane. 
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The immune complexes lead to glomerular damage through activation of the 
complement pathways. 
The factor most often associated with idiopathic, primary MN is autoantibodies 
against endogenous anti-phospholipase A2 receptor (anti-PLA2R) (98). New antigen 
candidates are continuously being reported, such as human leukocyte antigen (HLA) 
complex class II HLA-DQ alpha chain 1 (HLA-DQA1) (99) and superoxide dismutase 
2 (100, 101). Most recently detected in MN are autoantibodies against thrombospondin 
type-1 domain-containing 7A (THSD7A) (102). 
 
 
4.2.8 Experimental animal models 
 
Animal models are an indispensable tool for studying the mechanisms of FPE, 
proteinuria and the function of specific proteins in the glomerular filtration barrier. 
Above all, they enable insights of the different stages of proteinuria and FPE, from the 
onset and early stages, to fully developed disease. Based upon the area of interest there 
are now a vast number of different animal models available, for example Heymann’s 
nephritis with formation of in situ immune complex, models of hyperfiltration due to 
reduced number of nephrons and  neutralization of the podocytes glycocalyx, resulting 
in FPE (103). Last year a murine line consistently developing IgAN was designed 
(104).  
For our studies, we used two non-transgenic animal models of nephrotic syndrome; 
puromycin aminonucleoside (PAN) administration to rats, and adriamycin 
administration (ADR) to mice. The podocytes are toxically injured in both models. 
Puromycin interrupts the ribosomal protein translation and adriamycin leads to DNA 
inserts, both substances resulting in considerable proteinuria. Obviously, great caution 
must be taken when translating results from animal models to human pathology. 
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4.3 GENETIC ANALYSIS TECHNIQUES 
 
The introduction of next-generation sequencing (NGS) has truly revolutionized genetic 
testing in research and diagnostics. The techniques can be used to identify novel genes, 
link single-nucleotide polymorphisms (SNPs) to specific diseases and also provide 
information of the gene functions (105).  
The traditional DNA Sanger-sequencing is a highly sensitive tool for identification of 
mutations, but is most successfully used to detect disease genes already known. In 
order to analyze genetically heterogeneous diseases, the method would be extremely 
time consuming and expensive. Next-generation sequencing, on the other hand, are 
able to analyze multiple genes or even complete genomes within days. 
Next-generation sequencing involves sequencing techniques of variously sized targets 
and resulting data; from whole-genome sequencing and whole-exome sequencing to 
targeted sequencing which sequences specifically selected parts of the genome and 
gene panel sequencing of selected known and candidate disease-causing genes (106). 
Most commonly used is whole-exome sequencing. The method combines specifically 
targeted protein-coding DNA with massively parallel sequencing, resulting in the 
complete coding variation of an individual genome. Thus, this method has hugely 
enhanced the discovery of genes linked to, for example, nephrotic syndrome (107). 
Single nucleotide polymorphism (SNP) microarray analysis can be used to identify 
homozygosity in the genome and differences in gene copy numbers. Based upon this 
primary regional demarcation, the chosen area can then be more closely analyzed by 
NGS techniques. 
Chromatin immunoprecipitation with sequencing (ChIP-seq) perform genome wide 
analysis and detects transcriptional DNA-binding sites and histone modifications that 
are known to regulate gene expression. In contrast to array techniques, ChIP-seq is not 
limited by fixed ranges of probe sequences. The method only requires a small amount 
of DNA for analysis and do not involve the troublesome hybridization step. However, 
ChIP-seq relies on PCR amplification to detect visible signals and is expensive. 
Transcriptome profiling using RNA-sequencing (RNA-seq) can identify and position 
mRNA, non-coding RNA, and small RNA and further detect and quantify 
posttranslational modifications.  
Hopes are that the methodological development of NGS in combination with the 
continuous identification of disease-linked genes, will lead to more specifically targeted 
therapies.  
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5 AIM 
 
 
With the aim to characterize the function of novel glomerular proteins in the human 
glomerulus, a genomic-, proteomic-, and bioinformatic research program was launched 
by groups at KI and KTH. By collaboration with these groups, we have access to 
antibodies against newly identified glomerular proteins. The specifically produced 
antibodies, in combination with the biopsy material from the hospital’s bio bank offers 
a unique possibility to study the expression of novel proteins in the renal filtration 
barrier in normal and diseased kidneys. 
With the hypothesis that the molecular structures of the podocytes and SD are altered in 
proteinuric diseases with foot process effacement, we wanted to study the localization 
and distribution of specific structural proteins in the normal kidney and in glomerular 
disease. The novel glomerular proteins included in this thesis: Dendrin, Plekhh2 and 
Neph1. 
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6 ETHICAL CONSIDERATIONS 
 
 
Normal renal tissue was taken from unaffected kidneys that had been surgically 
removed because of localized carcinoma (study I-III) and from living, healthy kidney 
donors (study IV).  
All biopsies were taken for diagnostic purposes and re-examined to confirm the 
diagnosis.  
The material is used in agreement with the local ethical board. 
 (Dnr 1395–32/2005, 2010/579-31/1, 2014-2210-32). 
All animal experiment were conducted according to Swedish animal research 
regulations and approved by the local Board of Ethics. 
(D228/99, 1395-32/2005, S65/2001, S25/2002, S209/03 N250/11)  
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PRESENTATION OF THE STUDIES 
 
This thesis is composed of four articles, three published and one manuscript. 
 
Study I describes the cytosolic podocyte protein Dendrin, which previously have been 
identified in the brain and in mouse podocytes, associated to the actin cytoskeleton. As 
the regulation of the podocyte actin cytoskeleton is of considerable interest in 
glomerular diseases with FPE, we wanted to study the expression of Dendrin in MCNS. 
The expression of the protein Zona Occludens-1 (ZO-1), known to be localized close to 
the SD, was included for comparison. 
Study II focuses on the intracellular protein Plekhh2, an uncharacterized protein with 
strongest expression in the podocytes and in the testis. Zebra fish PLEKHH2 knock-
downs have shown changes in the capillary walls with thickening of the GBM and 
disorganization of the foot processes. The aim of this study was to identify interaction 
partners of Plekhh2, as these interactions are likely to indicate the proteins 
physiological functions, and to investigate the expression of Plekhh2 in human 
proteinuric disease.  
 
Study III examines the transmembrane protein Neph1 that forms a complex with 
Nephrin in the SD. With recent indications of the involvement of the Neph1-Nephrin 
complex in actin polymerization and in proteinuria, we wanted to study the expression 
of Neph1 and compare it to that of Nephrin in FSGS and MCNS, and in their 
corresponding experimental models Adriamycin Nephropathy (ADR) and Puromycin 
aminonucleoside nephrosis (PAN).  
 
Study IV returns to Dendrin. We semi-quantified nuclear Dendrin in renal biopsies from 
patients with IgA nephropathy (IgAN) (including IgAV) and Membranous 
Nephropathy (MN) using iEM, and analysed the glomerular gene expression with 
microarray. This study was inspired by recent findings of an increased occurrence of 
Dendrin-positive podocyte nuclei in IgAN, evaluated by immunofluorescence (IFL).  
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7 MATERIAL 
 
 
7.1.1 Human, normal renal tissue used as controls 
 
Study I-III:  normal renal tissues from unaffected parts of kidneys surgically removed 
because of localized carcinoma.  
Study IV: biopsy material from living, healthy kidney donors. The biopsy was taken 
immediately after the kidney was removed from the donor.  
 
7.1.2 Patients 
 
Patients, who fulfilled the criteria of MCNS, FSGS, IgAN, IgAV and MN clinically 
and
 
histopathologically, were chosen for the studies. Classification of FSGS was 
performed according to the Columbia system (65, 66). For study II we used the 
perihilar and tip lesion types as these are the most common variants of primary FSGS 
in our area.  The IgAN cases were classified according to the Oxford system (89, 90) 
based upon the presence of mesangial hypercellularity, segmental glomerulosclerosis, 
endocapillary hypercellularity, tubular atrophy/interstitial fibrosis, and additionally for 
presence of cellular or fibrocellular crescents 
 
 
7.1.3 Biopsy material 
 
All biopsies included in the studies were taken for diagnostic purposes. Immediately 
after the biopsy was taken, the material was evaluated by an experienced technician. 
Material for light microscopy, immunofluorescence and electron microscopy were 
prioritized as the histopathological diagnosis is based on these examinations (see 
below). If possible, e.g. if the biopsy material was large enough, small pieces of tissue 
were embedded for iEM. Recently we have been able to collect patient material for 
gene expression analyses, as discussed later.  
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7.1.4 Adriamycin Nephropathy (ADR) 
 
Adriamycin Nephropathy is a well-established experimental animal model of human 
FSGS (103). The administration of the toxin adriamycin leads to a progressive, chronic 
glomerular disease, characterized by proteinuria, segmental glomerulosclerosis, FPE 
and tubulointerstitial fibrosis. Formerly being a model based upon rats, Wang et al 
published a protocol for mice in 2000. The ADR method has greatly enhanced the 
understanding of the processes underlying the progression of renal injury (108).  
In our material (Study III) we could measure extensive albuminuria day 7 after 
injection, along with partial FPE. By day 14, segmental sclerotic lesions were present in 
the glomeruli of all animals except for one. This material allowed us to study the 
protein expression in the initial phase, as well as in fully developed disease with 
sclerotic lesions of the glomeruli. 
 
 
 
7.1.5 Puromycin aminonucleoside nephropathy (PAN) 
 
 Puromycin aminonucleoside is an antibiotic originating from the Streptomyces 
alboniger bacterium. Intravenous administration of the toxin results in proteinuria and 
FPE (109). PAN is believed to be converted by the podocyte xanthine oxidase to a 
toxic metabolite, leading to glomerular injury. In contrast to ADR it does not give rise 
to segmental sclerosis of the glomeruli until after 16 weeks, and is therefore used as an 
experimental model of MCNS. 
In our material (Study I, III), partial FPE was seen by day 2 after injection, before the 
onset of proteinuria by day 4. The FPE was widespread by day 4. No sclerotic lesions 
were present in the glomeruli (110). 
We used material from day 2 in order to study the protein expression prior to 
proteinuria and the material from day 4, presenting both proteinuria and FPE, as a 
comparison to human MCNS material. 
 
 
 37 
 
7.1.6 Gene expression profiling with Affymetrix 
 
Two mouse glomerular disease models were included in this analysis: 
Lipopolysaccharide (LPS)-induced nephrotic syndrome, a sub-septic mice model of 
transient proteinuria (111) and type II diabetic mice model (Norlin J. et al, manuscript). 
Mouse glomerular RNA was isolated and hybridized on Affymetrix arrays and the 
array data were processed as described before. 
 
7.1.7 Expression constructs 
 
Expression constructs were generated by the cloning of PCR-amplified fragments into 
various expression vectors. Inserts were amplified from kidney cDNA (Mouse MTC 
Panel I, Clontech Laboratories, Palo Alto, CA) with Long PCR Enzyme Mix 
(Fermentas International, Burlington, Canada), and sequenced to confirm the absence 
of PCR-generated mutations. The PCR program used was as follows: 1 cycle of 
951C/4 min, 30 cycles of 951C/1 min, 511C/1 min, 721C/2–10 min, and 1 cycle of 
721C/10 min. For yeast two-hybrid screening, inserts were cloned into the vector 
pGBKT7 (Clontech Laboratories) in frame with the Gal4 DNA-binding domain. For 
expression in mammalian cells, cDNAs were cloned into pcDNA3.1 (Invitrogen, 
Carlsbad,CA), or vectors with various N-terminal tags (pCMV-Myc, pCMVHA, 
or pEGFP-C; all from Clontech Laboratories). 
 
 
7.1.8 Cell cultures, transient and stable transfections 
 
Human podocytes were grown at 33ºC/5% CO2 in RPMI supplemented with 10% fetal 
bovine serum (Invitrogen), 1x insulin-transferrin-selenium-A supplement (Invitrogen), 
and antibiotics (100 U/ml penicillin and 100 µg/ml streptomycin) (Invitrogen), as 
previously described. HEK293, COS7, NIH3T3 and CHO cells were cultured at 
37ºC/5% CO2 in DMEM containing the same supplements, except ITS-A. Cells were 
transiently transfected with Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s recommendations. For generation of stable-expressing HEK293 clones, 
cells were selected and maintained in medium containing 500 µg/ml of G418. Stable 
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transfectants were characterized by GFP immunofluorescence and Western blotting for 
GFP expression. 
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8 METHODS 
 
 
8.1 IMMUNOHISTOCHEMISTRY 
 
Immunohistochemistry is used to define the localization of a biochemically defined 
antigen, i.e., to localize a specific protein in tissue or cell with an antibody directed 
towards the antigen. 
In order for the antibody to recognize the antigen in the tissue structure, it is of 
foremost importance that the protein structure is preserved as intact as possible. 
 
 
8.1.1 Primary antibodies 
 
In the preparation of polyclonal antibodies, the specific protein is biochemically 
isolated and injected in the animal. The immune response from the B-cells gives a large 
amount of antibodies directed towards different epitopes of the antigen, i.e. polyclonal 
antibodies. The IgG fraction (most commonly) is then filtered out for production. To 
produce monoclonal antibodies, one (1) specific B cell is isolated and cloned to 
produce antibodies directed against the same, specific, epitope. 
For immunohistochemistry (especially iEM) studies, polyclonal antibodies are 
preferred as the probability of one specific epitope, being exposed on the surface of the 
embedded tissue is very low. If the antibodies are directed against a number of 
epitopes, the probability of binding the specific protein increases. 
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8.2 TISSUE PREPARATION 
 
 
8.2.1 Tissue preparation for light microscopy 
 
Specimens were fixed in 4% phosphate buffered formaline, dehydrated and embedded 
in paraffin according to standard procedures. 1.5 µm sections were cut on a microtome, 
and stained with hematoxylin-eosin, periodic-acid Sciff (PAS), Ladewig trichrome, and 
periodic acid silver (PASM). 
 
 
8.2.2 Immunofluorescence, human material 
 
An unfixed piece of the renal biopsy taken for diagnostic purposes was snap frozen. For 
diagnostic purposes, 5 µm thick cryosections were incubated with FITC-conjugated 
antibodies against IgG, IgA, IgM, fibrinogen, the light chains kappa and beta and the 
complement factors C3 and C1q. 
For our studies of novel glomerular proteins, the cryosections were postfixed with cold 
acetone (−20°C) and blocked in 5% normal goat serum. Primary antibodies were 
incubated overnight at 4°C and the secondary fluorescent antibody for 1 hour in 
darkness, in room temperature. 
 
 
8.2.3 Immunofluorescence, cultured cells 
 
Cells were grown on fibronectin-coated glass coverslips. For coating, coverslips were 
incubated with 10 mg/ml of fibronectin (Invitrogen, 33010-018) for 2 h at room 
temperature, followed by several washes with phosphate-buffered saline (PBS). Cells 
were fixed with 4% paraformaldehyde solution for 20 min at room temperature, after 
which they were permeabilized by incubation with 0.1% Triton X-100/PBS for 5 min, 
followed by an incubation with 2% bovine serum albumin/PBS (blocking solution) for 
1 h. In some experiments, cells were treated with 0.5% saponin/PBS for 20 min before 
fixation. After blocking, cells were incubated with primary antibodies for 1 h at room 
temperature, washed several times with PBS, and then incubated for 1 h with a suitable 
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secondary antibody. All antibodies were diluted in the blocking solution. Secondary 
antibody solutions also contained rhodamine–phalloidin and 4,6-diamidino-2-
phenylindole to stain F-actin and cell nuclei, respectively. For double labeling, 
incubations were performed sequentially to prevent cross-reactions. Photos were taken 
using Zeiss LSM510 confocal microscope, with X 20, X 40, or X 63 objectives. 
 
 
8.2.4 Drug treatment of cells 
 
Transiently transfected human podocytes were plated on fibronectin-coated coverslips 
in 24-well plates, and left to adhere and spread for 16 h. Thereafter, cells were 
incubated for 1 h at 371C with 100 nmol/l of wortmannin (Sigma, W1628) or 50 
mmol/l LY294002 (Cell Signaling, 9901), inhibitors of phosphatidylinositol 3-kinase, 
or 10 mg/ml of the actin monomer–sequestering drug latrunculin A (Sigma, L5163), 
all diluted from stock-solutions prepared in dimethylsulfoxide. Control cells were 
incubated with the vehicle only. After the incubation, cells were fixed and stained for 
Myc-tagged Plekhh2 and F-actin as described above. 
 
 
 
8.2.5 Immunoperoxidase staining 
 
2, 5 µm sections of paraffin-embedded tissue were pre-treated with tris-EDTA (Dako, 
Glostrup, Denmark) followed by 3% H2O2 in methanol. 10% milk was used as blocking 
for 30 minutes. The primary antibody, or normal IgG as negative control, was 
incubated overnight after which the HRP-conjugated secondary antibody (Envision 
TM, Dako, Glostrup, Denmark) was added for 30 minutes at room temperature and 
then visualized by the DAB/ H2O2 substrate. Nuclei were stained by hematoxylin. 
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8.3 ELECTRON MICROSCOPY (EM) 
 
The resolution in light microscope is limited by the wavelength of the light (350-700 
nm). Replacing light by electrons (0,002 nm) gives better resolution and the possibility 
to study the ultrastructure of the tissue. Compared to the 5000 nm tissue sections that 
can be examined with light microscopy, the EM equivalents are as thin as 50 nm and 
the resolution is approximately 0,1 nm, in contrast to the 300 nm of LM.  
Electron microscopy is a black and white technique. In order to identify structures, the 
contrast in the tissue material must be enhanced.  
Tissue used for TEM requires a special fixation and embedding protocol.  
 
 
 
8.3.1 Tissue preparation for transmission electron microscopy 
 
Tissue were fixed in a phosphate buffered 2% glutaraldehyde, and post-fixed in 
osmium tetraoxide (OSO4) in order to enhance contrasts. After alcohol dehydration 
followed by acetone, the specimen were embedded and polymerized in a plastic resin to 
enable the ultrathin sectioning of approximately 40- 60 nm. The specimen were then 
mounted on a formvar coated grid and finally contrasted by adding the heavy metals, 
lead citrate and uranyl acetate. 
 
 
8.3.2  Immuno Electron Microscopy (iEM) 
 
Small pieces of tissue were dehydrated at low temperature in methanol and embedded 
in
 
Lowicryl K11M (Chemische Werke Lowi, GmbH, Waldkreiburg, Germany), a 
special resin which enables iEM. Ultrathin sections were mounted on carbon/formvar 
nickel grids and incubated in
 
2% bovine serum albumin (BSA) and 2% gelatin in 0.1 M 
phosphate buffer (PB) at
  
pH 7.4 followed by incubation overnight
  
with primary 
antibodies (Dendrin, Plekhh2, Neph1 and Nephrin), diluted 1:100 and 1:50 
respectively, in 0.1M PB containing 0.1% BSA and 0.1% gelatin (PBBG). Bound 
antibodies were detected by protein A conjugated with 10 nm colloidal gold
 
(Biocell 
Laboratories Inc., Rancho Dominguez, CA, USA), diluted 1:100 in PBBG. 
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When double staining Neph1 and Nephrin, Nephrin was incubated overnight, followed 
by Neph1 for 3 hours. Secondary antibodies conjugated with 5 nm and 10 nm gold 
particles respectively were used to detect the bound antibodies.  
 
 
8.3.3 Semiquantification of structural proteins by iEM 
 
The primary antibody is detected by protein A molecule tagged with a 10 nm gold 
particle which, due to its high density, allows visualisation by electron microscopy. 
Protein A derives from Staphylococcus Aureus and is used because of its specific 
binding to the Fc part of the IgG molecule. Protein A binds to the IgG molecule in the 
ratio of 1:1, thereby allowing semi-quantification. Protein A also gives lower 
background compared to the use of secondary antibodies which can bind multiple 
epitopes of the IgG molecule.  
Sections
 
were examined in a Tecnai 10 microscope (FEI Company, the Netherlands) 
and digital images were taken by a Veleta camera (SiS Company, Münster, 
Germany). 
 
 
Figure 14a. Semi quantification by iEM. Six locations of the glomerulus were chosen according to a 
random systematic sampling procedure. 14b. Gold markers identified in the podocytes. 
 
Six locations
 
per glomerulus (1–2 glomeruli, depending on material) were chosen with 
a random start at low magnification along the glomerular
 
capillaries. Three images were 
systematically taken from each location,
 
including areas with or without foot process 
effacement (no sclerotic areas), giving a minimum of 18 images/specimen (Figure 14a). 
Prints at a final magnification of 52 000× were
 
examined and the number of gold 
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markers (Au) was counted in the podocytes, GBM and endothelial cells, respectively. 
In study IV, a minimum of 8 images/biopsy were also taken of the podocytes nuclei. 
The area of the different compartments were calculated by point counting, using a 1 × 1 
cm square lattice (112), and expressed as µm
2
. Dividing the total number of gold 
particles by the area, give the concentration (Au/µm
2
) (Figure 14b).  
In order to distinguish between areas with and without FPE, the length of the GBM was 
measured and the number of slits/µm GBM calculated. Less than 1 slit/µm GBM was 
defined as FPE.  
 
8.3.4 Yeast two-hybrid screening  
 
For yeast two-hybrid screening, we used a mouse kidney glomerulus cDNA library 
custom-generated by Clontech. The library was screened with baits encoding the Gal4 
DNA-binding domain fused to full-length Plekhh2 or its deletion variants. Screening 
was carried out by yeast mating according to the manufacturer’s instructions. Diploids 
were selected through several rounds of culture on minimal synthetic dropout medium. 
Plasmids from obtained colonies were isolated, sequenced, and analyzed with the 
BLAST algorithm at the National Center for Biotechnology Information (NCBI). 
 
8.3.5 Western blotting 
Western blot separates proteins based on molecular weight through gel 
electrophoresis. The proteins are then transferred from the gel of the electrophoresis 
to a membrane where they can be bound, and thereby identified, by specific 
antibodies. This binding is then visualized by exposure of the membrane in a dark 
room. The amount of protein can be estimated by the thickness of the band seen. 
Western blotting for the Plekhh2 study was carried out following standard procedures. 
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8.3.6 Co-immunoprecipitations  
 
Confluent transiently transfected HEK293 cells were washed twice in cold PBS and 
lysed in 0.5% Triton X-100, 20 mM Tris-HCl (pH 7.4) and 150 mM NaCl buffer 
containing protease inhibitor cocktail (Roche) and phosphatase inhibitors (1 mM 
NaVO3, 50 mM NaF). Lysates were clarified by centrifugation (14000 x g), incubated 
with primary antibodies overnight, followed by an incubation with protein A+G 
agarose beads (Roche Molecular Biochemicals) for 1 h at 4°C. Thereafter the beads 
were washed 3 times with the lysis buffer, resuspended in 1x SDS-sample loading 
buffer, and boiled for 10 min. Eluted proteins were analyzed by SDS-PAGE and 
Western blotting. For subcellular fractionation experiments, cell lysates were 
fractionated with Qproteome Cell Compartment Kit (Qiagen) prior to gel analysis. 
 
 
8.3.7 Fluorescent Resonance Energy Transfer (FRET) in fixed cells  
 
A detailed description of the FRET technique can be found elsewhere (113). We 
utilized this method to confirm dimerization of the Plekhh2 protein using human 
podocytes cotransfected with GFP- and Myc-tagged versions of Plekhh2. The Förster 
constant, R0, for the donor-acceptor pairs used in this study, Alexa488 and Alexa568, 
is 62Å. To determine FRET, we quantified the quenching of donor fluorescence by 
performing acceptor photobleaching. FRET measurements were performed using a 
Zeiss LSM510 inverted confocal microscope, apochromat 63x/1.4 NA oil immersion 
objective and the Zeiss LSM510 software version 2.8. Briefly, fluorophores were 
excited with 488 and 543 nm laser and images collected separately. The acceptor, 
Alexa568, was then irreversibly photobleached in a selected adequate region by 
continuous excitation with a 543 nm laser for about 30 s. Thereafter, residual Alexa568 
and Alexa488 image was obtained under same settings as prebleach images, and 
identical regions on individual cells were outlined in the photobleached area and 
processed using ImageJ. Ratios between Alexa488 intensities of the selected region, 
after and before photobleaching, were calculated to quantify FRET. In a typical 
experiment 15–20 cells were measured for each sample.  
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8.3.8 In vitro actin polymerization and depolymerization assays  
 
In vitro actin polymerization and depolymerization assays using the Actin 
Polymerization Kit (Biochem) were employed to study the role of Plekhh2 in the actin 
assembly processes. The assay relies on the difference between fluorescent signals of 
pyrene-labeled monomeric G-actin and polymerized pyrene-F-actin (used as positive 
controls in our experiments). For these assays, we used lysates prepared from 293 cells 
stably expressing GFP-Plekhh2, and control cells. Cells were plated onto plates coated 
with 10 µg/ml of fibronectin, and allowed to adhere overnight in a serum-free media, 
followed by an overnight treatment with medium containing 10% FCS or 30 µg/ml of 
PDGF-BB (Invitrogen). After this, cells were collected and lysed for 3 h at 4°C in a 
buffer containing 20 mM Tris-Cl, pH 7.5, 20 mM NaCl and protease inhibitors. Lysates 
were clarified by centrifugation at 14000 rpm for 50 Perisic!Ljubica 50 10 min. The 
actin polymerization and depolymerization assays were performed according to 
manufacturer’s instructions, and fluorescence kinetic measurements were done with 
TECAN GENiosPro.  
 
8.3.9 Live cell imaging (Article II, supplementary) 
 
Imaging of GFP-Plekhh2-expressing human podocytes plated on fibronectincoated 
glass coverslips was started immediately after cell plating. Imaging was continued 
overnight, with images being taken every 5 min (Zeiss LSM 510 microscope, 40 X 
objective). They were then processed into a movie with the ImageJ program.  
 
8.3.10 Glomerular microdissection 
 
Immediately after biopsy procedure, the renal tissue material was placed on a drop of 
RNA Later. The material was then placed in the fridge for a minimum of 24 hours and 
thereafter in a – 20 or -80 degrees Celsius freezer. The glomeruli were isolated from the 
renal tissue under a dissection microscope and placed on a drop of RNA Later. The 
glomeruli were transferred to an Eppendorf tube containing 350 µl RLT lysis buffer 
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(Qiagen, Netherlands). 3,5 µl β-mercaptoethanol was added, and the sample vortexed 
for 1 minute. The sample was then quick-freezed. 
 
8.3.11 Microarray analysis 
 
The total RNA from microdissected glomeruli was extracted using RNeasy® Mini Kit 
(Qiagen, Netherlands). Microarrays were performed on human genome U133 plus2.0 
array (Affymetrix, Santa Clara, Calif., USA) by the Bioinformatics and Expression 
Analysis Core Facility (BEA) at Karolinska Institutet using standard protocols. 
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8.4 DATA COLLECTION AND STATISTICS 
 
The material used for iEM must be saved and embedded prospectively. Thus, such 
material can only be prepared if the biopsy is large enough to still allow a proper 
histopathologic examination. This means that for material from a certain disease we 
must both rely on the biopsy quality, the amount of material from the biopsy, and the 
general prevalence of the specific disease in our area. The relatively small number of 
cases representing each specific disease can be rather troublesome when it comes to 
statistics. 
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9 RESULTS 
 
 
9.1 MAIN FINDINGS STUDY I 
 
In normal renal tissue, IFL showed Dendrin in almost complete overlap with Nephrin 
(used as an SD marker) in a linear pattern along the glomerular capillaries. With EM 
we could localize 36% of Dendrin close to the SD. 
Neither the staining pattern nor the intensity of Dendrin or ZO-1 differed between 
MCNS and controls, using IFL. This was confirmed by iEM. No significant change in 
the total amount of Dendrin or ZO-1 was seen in MCNS compared to controls, neither 
in areas with or without FPE (Table 1). Both Dendrin and ZO-1 were redistributed from 
the SD to the podocyte cytoplasm in FPE areas. The amount of Dendrin in the nuclei of 
PAN was unchanged compared to controls (Table 2). 
 
Dendrin expression in the podocytes in human kidney 
 Slits/µm Au/µm
2
 Au/slit Percentage of 
Au on slits 
Controls 
(n=5) 
1,8  0,3 1,2  0,4 0,1  0,0 36  12 
MCNS, areas 
with FPE 
(n=5) 
0,5  0,1 0,9 0,3 0,1  0,1 17  9* 
MCNS, areas 
without FPE 
(n=5) 
1,6   0,3 1,5  1,0 0,2  0,1 32  4 
Table 1. Expression of Dendrin in controls and MCNS based on iEM, gold particles/µm
2
 
(Au/µm
2
). The data are presented as mean ± sd, * = p < 0.05 compared to controls. 
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Dendrin expression in the podocyte nucleus in rat 
 
Controls 1,2  0,3 
PAN 1,3  0,5 
Table 2. Expression of Dendrin in controls and MCNS based on immunoelectron microscopy, 
gold particles/µm
2
 (Au/µm
2
). The data are presented as mean ± sd. 
 
 
 
 
9.2 MAIN FINDINGS STUDY II 
 
Using IFL and iEM we localized Plekhh2 to the podocyte foot processes in the normal 
human glomerulus. The protein was mainly found centrally in the foot process 
cytoplasm (56%) or close to the plasma membrane (within a distance of 100 nm, 
28%). Some expression was also seen close to the GBM (12%) but rarely in the SD. 
We showed that Plekhh2 is present in the membrane and cytoskeletal fractions of 
cultured human podocytes, which suggests that it is associated to these structures. 
Yeast-two hybrid (Y2H) screening identified Hic-5 and β-actin as interacting partners 
of Plekhh2. With iEM we could visualize the co-localization of Plekhh2 and Hic5 in 
the podocyte foot processes close to the GBM. 
In cells treated with actin monomer-sequestering drug, Plekhh2 stabilizes the cortical 
actin cytoskeleton, possibly by diminishing actin depolymerization. 
Semi-quantification by iEM showed Plekkh2 to be significantly reduced in primary 
FSGS of perihilar and tip lesion types, compared to controls. There was a re-
distribution from the plasma membrane to centrally in the foot processes in the tip 
lesion type. This was also identified in perihilar FSGS, although not statistically 
significant. There was no significant change in the overall amount of Plekkh2 in MCNS 
and MN, except for a reduction in non-FPE areas in MCNS (data not published) (Table 
3). We also found Plekhh2 to be unchanged in Diabetic Nephropathy (DN) compared 
to controls (Table 4). As a different batch of Plekhh2 antibodies was used for the DN 
cases, we calculated these separately, and compared to the controls incubated 
concurrently. 
 We found no correlation between the amount of Plekhh2 and degree of proteinuria and 
slits/µm GBM (data not shown). 
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Plekhh2 expression (Au/µm
2
) in podocytes in human kidney 
 Total amount 
in podocytes  
FPE 
 
Non-FPE 
areas 
 
Controls            
(n = 5) 
1.8 ± 0.5 1.8 ± 0.4 - 
Perihilar 
FSGS (n = 5) 
  0.7 ± 0.2* 1.2 ± 0.2 0.7 ± 0.2* 
Tip lesion 
FSGS (n = 5) 
1.1 ± 0.2 1.2 ± 0.2 1.0 ± 0.4* 
MN (n = 5) 1.5 ± 0.5 2.4 ± 0.4 1.4  ± 0.4 
MCNS (n = 5) 1.3 ± 0.4 2.2 ± 1.5 1.0 ± 0.2* 
Table 3. Expression of Plekkh2 in controls, perihilar FSGS and tip lesion FSGS based on 
immunoelectron microscopy, gold particles/µm
2
 (Au/µm
2
). The data are presented as mean ± 
sd, * = p < 0.05 compared to controls. 
 
 
Plekhh2 Total 
amount 
FPE No FPE 
Controls (n = 4) 1.4 ± 0.1   
DN (n = 4) 1.2 ± 0.1 1.1 ± 0.2 1.5 ± 0.2 
Table 4. Expression of Plekkh2 in controls and DN based on immunoelectron microscopy, gold 
particles/µm
2
 (Au/µm
2
). The data are presented as mean ± sd, 
 
 
 
9.3 MAIN FINDINGS STUDY III 
 
With iEM we localized Neph1 mainly to the SD in normal human, rat and mouse 
kidney. Double iEM staining of Neph1 and Nephrin showed the proteins in close 
connection in the SD. This is, to our knowledge the first published EM image of the co-
localization, and also of Neph1 in human kidney (page 149). 
We found Neph1 to be significantly reduced in the podocytes both in areas with and 
without FPE in perihilar FSGS and in MCNS (Table 5), with iEM. This reduction was 
also seen in the corresponding experimental models PAN and ADR (Table 4). Nephrin 
was unchanged in FSGS and ADR, both in areas with and without FPE, but reduced in 
MCNS and PAN (Table 6). The expressions of Neph1 and Nephrin are compared and 
summarized in table 7. 
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Expression of Neph1(Au/µm
2
) in podocytes in human kidney 
 
 Proteinuria 
(g/24h) 
Total amount 
in podocyte  
FPE  Non-FPE 
areas  
Controls 
(n=5) 
0 1,5 ± 0,2 - - 
FSGS      
(n=5) 
1 g/24 h- 8 
g/24 h.  
  0,3 ± 0,1* 0,3 ± 0,2* 0,5 ± 0,3* 
MCNS    
(n=5) 
1g/l – 27g/24 h   0,5 ± 0,1* 0,5 ± 0,1* 0,5 ± 0,2* 
Table 5.  Expression of Neph1 in controls, FSGS and MCNS based on immunoelectron 
microscopy, gold particles/µm
2
 (Au/µm
2
). The data are presented as mean ± sd, * = p < 0.05 
compared to controls 
 
 
 
Expression of Nephrin (Au/µm
2
) in podocytes in human kidney 
 
 Proteinuria 
(g/24h, g/l) 
Total amount 
in podocyte  
FPE   Non-FPE 
areas   
Controls (n=4)  0 2,4 ± 0,6 - - 
FSGS      (n=4)  1g/24 h- 8g/24 h.  2,0 ± 0,4
 
2,3 ± 0,4 1,4 ± 0,0
◄ 
MCNS    (n=5)  1g/l – 27g/24 h 1,0 ±-0,2* 0,9 ± 0,2* 1,2 ± 0,4* 
Table 6.  Expression of Nephrin in controls, FSGS and MCNS based on immunoelectron 
microscopy, gold particles/µm
2
 (Au/µm
2
). The data are presented as mean ± sd, * = p < 0.05 
compared to controls. ◄= Only one observation 
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Summary of Neph1 and Nephrin findings 
 Neph1 Nephrin 
FSGS ↓ → 
FSGS, FPE ↓ → 
FSGS, Non FPE ↓ → 
MCNS ↓ ↓ 
MCNS, FPE ↓ ↓ 
MCNS, Non FPE ↓ ↓ 
ADR, Day 7 ↓ → 
ADR, Day 7, FPE ↓ → 
ADR, Day 7, Non FPE ↓ → 
ADR, Day 14 ↓ ↓ 
ADR, Day 14, FPE ↓ → 
ADR, Day 14, Non FPE ↓ → 
PAN, Day 2 ↓ ↓* 
PAN, Day 2, FPE → ↓* 
PAN, Day 2, Non FPE ↓ ↓* 
PAN, Day 4 ↓ ↓* 
PAN, Day 4, FPE ↓ ↓* 
PAN, Day 4, non FPE ↓ ↓* 
Table 7.  Summary of findings based on immunoelectron microscopy. 
Notes: ↓ = significantly reduced (p < 0,05), → = no change compared to controls. 
*= Previously published (40). 
 
 
 
9.4 MAIN FINDINGS STUDY IV 
 
Semi-quantitatively, by iEM, we found the amount of Dendrin to be significantly 
increased in the podocyte nuclei in IgAN (Table 8), with and without nephrosis, 
compared to controls. The amount of nuclear Dendrin was unchanged between the 
morphologically based Oxford groups (89, 90) of mesangial hypercellularity, segmental 
glomerulosclerosis, endocapillary hypercellularity, tubular atrophy/interstitial fibrosis 
and crescents. Nuclear Dendrin was also unchanged in IgAV (Table 8). 
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The Dendrin expression in the podocyte cytoplasm was unchanged in IgAN as a group 
compared to controls. There was, however, an increase of Dendrin in the podocyte 
cytoplasm in IgAN cases without crescents. 
The amount of nuclear Dendrin was not correlated to whether the patient had nephrosis 
or not, nor to renal disease progression, measured as mean loss of glomerular filtration 
rate (eGFR). There was however, a significant correlation between negative renal 
progression and the Oxford groups of mesangial hypercellularity, segmental 
glomerulosclerosis and tubular atrophy/interstitial fibrosis compared to the cases 
without these morphological characteristics.  
Microarray analysis revealed a two fold increase in glomerular gene expression of 
Dendrin in IgAN.   
Both gene and protein expression of Dendrin was unchanged in MN.  
 
 
Expression of Dendrin (Au/µm
2
) in podocyte nuclei and cytoplasm 
Dendrin Podocyte nuclei Podocyte 
cytoplasm 
Controls (n=5) 0,4 ± 0,1 1,5 ± 0,6 
IgAN (n=19)   0,7 ± 0,0* 2,0 ± 1,0 
IgAN with neprosis 
(n= 6) 
0,8 ± 0,3 2,1 ± 1,4 
IgAN without 
nephrosis (n=13) 
0,7 ± 0,3 1,9 ± 0,8  
MN (n=5) 0,3 ± 0,1 1,4 ± 0,5 
IgAV (n=5) 0,6 ± 0,2 1,2 ± 0,6 
Table 8. Expression of Dendrin in controls, IgAN and MN based on immunoelectron 
microscopy, gold particles/µm
2
 (Au/µm
2
). The data are presented as mean ± sd, * = p < 0.05 
compared to controls. 
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10 DISCUSSION 
 
 
10.1 REFLECTIONS ON METHODS  
 
10.1.1 Strengths/ Weaknesses of methods 
 
As from study IV we have been able to use biopsy material from living, healthy kidney 
donors as controls. The biopsy is taken immediately after the kidney is removed from 
the donor, which means that ischemic damage to the material is minimized. When 
studying protein expression in the renal filtration barrier, EM has the great advantage 
over light microscopy that it can be used to closely observe specific cellular or 
subcellular structures. The method also enables identification of different 
morphological changes, e. g. differentiating between areas with and without FPE. 
This means that the amount of protein can be evaluated in normal and effaced areas, 
respectively. The iEM technique that we have developed to semi-quantify the 
expression of proteins is robust and well established in our department. However, due 
to the limited amount of specially embedded material there are sometimes statistical 
difficulties, as mentioned earlier.   
We have recently initiated a renal project aiming to systematically collect material from 
patients undergoing biopsy procedure. In addition to the biopsy material, blood and 
urine are also collected, for analysis of known and new biomarkers. Using small pieces 
of the biopsy material, gene expression can be mapped with for example microarray 
analysis. These results of up- and down regulated genes, can then point to specific 
proteins worth further investigations with immuno-techniques. The constituent material 
of this project is still very limited but a fair number of biopsies from the most common 
diseases, such as IgAN and MN have been collected. These cases were indeed used for 
the microarray analysis of study IV.   
 
The experimental models of PAN and ADR are valuable tools when assessing changes 
in protein expression in relation to proteinuria and FPE, and as supplements to human 
disease material. Though, it is very important that these models are not treated as 
representations of human glomerular diseases, and as mentioned earlier, that the results  
are not readily applied to human pathology. Mainly because the toxic injury of the 
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podocytes in these experimental models is both toxically specific and acute, which 
affect the molecular composition of the filtration barrier differently than in the slow 
chronic progression of MCNS and FSGS (103, 113). 
 
 
 57 
 
 
10.2 REFLECTIONS ON RESULTS 
 
10.2.1 Study I and IV 
 
Considering the unchanged amount of Dendrin and ZO-1 in areas with and without 
FPE, the proteins are probably being redistributed from the SD to the podocyte 
cytoplasm, secondary to FPE. This pattern differs from our Nephrin and Neph1 results 
in MCNS, where both proteins are reduced in areas with FPE as well as in areas 
without, and therefore would be more probable key players in the processes behind 
FPE. 
 
Since our first Dendrin publication, the most probable function of the protein is 
currently believed to be that of an apoptotic modulator in the podocytes. Recent years 
studies of Dendrin have focused on the fact that it seems to accumulate in the podocyte 
nucleus in response to glomerular injury, and its bindings to proteins associated to 
apoptosis. 
In 2011 Asanuma Ket al (115) showed an accumulation of Dendrin in podocyte nuclei 
in ADR mice and in patients with FSGS and MN. In line with our earlier results 
(unchanged expression in PAN), they did not find nuclear Dendrin in MCNS patients.  
Kodama F et al saw a similar nuclear translocation of Dendrin in patients with IgAN, 
evaluated by IFL (116).  
This inspired us to continue our Dendrin study with IgAN patients to further examine 
the nuclear translocation, possible correlation to the morphology of the Oxford system 
and disease progression.  
With unchanged Dendrin expression in the proteinuric diseases MCNS and MN and no 
correlation between nuclear amount and nephrosis in IgAN, we do not believe Dendrin 
to be associated to proteinuria. 
We found Dendrin to be increased in the podocyte nuclei in IgAN, and its gene 
expression correspondingly up-regulated. These results support the hypothesis that the 
main function of Dendrin is that of an apoptotic inducer in injured podocytes, possibly 
linked to the development of chronic glomerular injury. The proposition by Asanuma et 
al (115) that nuclear Dendrin could serve as a marker of disease activity and prediction 
of progression to glomerulosclerosis in biopsy material is, however, not supported by 
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our results. Neither did we find the amount of nuclear Dendrin in the individual IgAN 
cases to be correlated to renal disease progression, nor to crescents. This could be due 
to difficulties to capture the immediate peak of nuclear translocation or ongoing 
fluctuations. Experimental models would make it possible to closely monitor the 
nuclear translocation of Dendrin in the course of glomerular injury. But, as earlier 
discussed, the acute and toxically known insult to the podocytes, is not a faithful model 
for acquired glomerular disease, in human. 
 
 
 
10.2.2 Study II 
 
Plekhh2 seemingly affect the foot process dynamics by attenuating actin 
depolymerization and thereby stabilizing the cortical cytoskeleton. Plekhh2, and the 
Y2H identified interaction partners Hic-5 and actin, were all downregulated in the 
experimental mice model lipopolysaccharide (LPS) of FPE and reversible proteinuria, 
which suggest involvement in this induced injury. We identified a re-distribution of 
Plekhh2 from the plasma membrane to centrally in the foot processes in both FSGS 
variants, although not statistically significant in the perihilar type. 
The only previous publication of Plekhh2 indicating an involvement in human renal 
disease, is a study by Greene et al. (117), who found sequence variants in the 
PLEKHH2 gene to be associated to development of Diabetic Nephropathy (DN). He et 
al (111, supplementary material) were, however, unable to replicate these results. These 
later findings (111) are further supported by our iEM data showing unchanged Plekhh2 
expression in DN cases compared to controls (unpublished data, table 4). Though, the 
number of cases available was limited since biopsies are rarely performed on DN 
patients.  
No other study on the expression or involvement of Plekkh2 in human glomerular 
disease has, to our knowledge, been published since. 
 
 
 
 59 
 
10.2.3 Study III 
 
The reduction of Neph1 in combination with unchanged amounts of Nephrin in FSGS 
could indicate a dissociation of the proteins from the complex.  
Since the publication of our study, Takahashi et al (118) have found Neph1 and 
Nephrin to be significantly reduced in PAN, in line with our results. They showed that 
the IFL staining of both proteins shifted to a discontinuous pattern 1 hour after PAN 
injection and that the mRNA expression was reduced to undetectable levels. Treatment 
with Angiotensin II receptor blockade (ARB) prevented the reduction. Fascinatingly, 
when control rats where treated with ARB, their mRNA expression of Neph1 and 
Nephrin increased to 281% and 154% respectively.  Exactly how the proteins are 
regulated and affected by Angiotensin II action will be interesting to follow.  
Suvanto et al (119) have detected a 46-fold decrease of Neph1 in congenital nephrotic 
syndrome of the Finnish type (CNF) compared to controls, evaluated by 
immunoperoxidase and IFL. This being particularly interesting as the disease is caused 
by a mutation of the NPHS1 gene, encoding for Nephrin. We also have indications of 
Neph1 being reduced in CNF but with only two cases available for iEM, we did not 
include these data in the article. Consequently, Neph1 could be part of the CNF 
pathology. Suvanto et al further, in contrast to our results, reported Neph1 to be only 
marginally reduced in MCNS, with and without proteinuria, evaluated from 
immunohistochemistry. 
Despite the fact that Neph1 -/- mice show severe nephrotic syndrome and early 
postnatal lethality, no mutations in the NEPH1 gene have been identified in human 
disease. However, considering the proteins wide expression pattern, involving heart, 
lung, placenta, brain, spleen and gut, a serious defect would probably not be compatible 
with life. 
We aimed to expand the study of the Neph1- Nephrin complex to double and 
traditional IFL staining. Unfortunately we did not have frozen biopsy material of 
sufficient quality from FSGS patients. A further complication was that the Neph1 
antibody did not work in paraffin embedded material despite numerous different 
protocols.  
The published results on the Nephrin expression in acquired kidney diseases are rather 
conflicting. Patrakka et al. (120) found no change in Nephrin expression in FSGS, 
neither evaluated by immunohistochemistry nor at mRNA levels. Koop et al. (121) 
have reported the direct opposite in FSGS, a marked reduction of the Nephrin protein 
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and an increase at mRNA level. Kim et al. (122) concluded that the expression pattern 
in proteinuric diseases varies according to the severity of glomerular damage. Also, 
despite many attempts to portrait a correlation between the expression of Nephrin in 
glomerular diseases and the degree of proteinuria, the results are highly inconsistent 
(123). 
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6   CONCLUSION 
 
The podocyte slit diaphragm, connected to the underlying GBM, and to the actin 
cytoskeleton, co-ordinate signals, initiated by external stimuli, that regulate the 
structure of the foot processes, and thereby, probably the function of the glomerular 
filtration barrier. 
When podocytes are injured, from such as immunological, toxic, metabolic, viral, 
ischemic or genetic causes (14, 51), the remodeled actin cytoskeleton is visualized as 
retracted or extended foot processes. This architectural alteration can then either be 
reversed to complete recovery or worsened. Additional insults to the podocyte can 
result in detachment from the GBM or apoptosis (124, 125). If  podocytopenia is 
widespread, sclerotic lesions will develop. Extensive global sclerosis might further lead 
to end stage kidney disease (58, 59). The exact mechanisms are, however still mainly 
uncharacterized, alongside most proteins and signalling pathways of the slit diaphragm. 
 
With IFL and iEM we have localized Dendrin and Neph1 to the SD and Plekhh2 to the 
cytoplasm of podocyte foot processes. 
At the SD, Dendrin binds Nephrin and CD2AP - an adaptor protein that can repress 
pro-apoptotic TGF-β signaling (126). Nephrin also binds Neph1 and Podocin, forming 
a transmembrane receptor complex. The cytoplasmic part of Nephrin binds intracellular 
adaptor proteins, such as ZO-1, CD2AP and Nck, which interacts either directly with 
the actin cytoskeleton or indirectly through actin-binding proteins. The extracellular 
domain of Nephrin interacts with other Nephrin molecules in the neighboring foot 
process. The genetic deletion of Neph1 and Nephrin independently, both lead to FPE, 
proteinuria and high perinatal mortality (38).  
It has also been identified that Neph1 is phosphorylated in injured glomeruli of 
different in vivo models (52, 127-129). 
The knowledge of the trigger behind actin transformation dynamics is very limited but 
the Neph1-Nephrin complex has been shown to be phosphorylated following protamine 
sulphate (PS) perfusion, an animal model resulting in immediate FPE (127, 130). 
Additionally, the Neph1-Nephrin complex regulates the actin associated protein 
Cofilin-1 which is needed for the cytoskeletal reconstruction following this injury 
(131).  
 62 
 
Arif et al (132) recently demonstrated that inhibition of Neph1 phosphorylation and 
prevented loss of Neph1 expression at the podocyte cell membrane, protected against 
PAN induced FPE. Impaired Nephrin-actin signaling has also been shown to inhibit the 
development of FPE (25). Altogether, this proposes Neph1and Nephrin signaling as 
an important, if not the main, event in response to glomerular injury and inducer of 
cytoskeletal rearrangement through further cascade initiation. 
An additional association to cytoskeletal dynamics is seen with our Plekhh2 findings. 
The protein seems to stabilize the cortical cytoskeleton by attenuating de-
polymerization, through its actin binding. 
Dendrin-deficient mice show unaffected glomerulogenesis and healing process of 
induced glomerular injury (133). However, even though apoptosis is undeniably 
present during development, it is most likely that these early signaling pathways differ 
from those operating in the mature podocyte. 
Although protein functions and signaling pathways of the SD are unraveling constantly, 
the complexity of the proteins interplay, signaling cross-talk and the unidentified 
extracellular ligands for SD proteins will continue to complicate the mapping and the 
understanding of podocytes in health and disease. 
Different insults to the podocyte may induce diverse signaling pathways via different 
proteins and separate mechanisms, but still lead to similar or identical adaptations of 
the podocyte actin cytoskeleton. This could suggest that although the morphology is 
artificially identical, the underlying disease trigger could give unseen deviations that 
decide upon the outcome. 
This is possibly highlighted by our results of a decreased amount of Neph1 in FSGS, 
while Nephrin is unchanged, and by the nuclear translocation of Dendrin in IgAN, but 
not in MN, all displaying FPE and proteinuria. 
Whether the foot process effacement is a pure defense mechanism aiming to protect the 
barrier and prevent protein leakage as proposed by Kriz et al (50), or an altogether 
independent factor to proteinuria, will probably remain the perplexity of renal 
pathology for some time. 
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7 CLINICAL SIGNIFICANCE 
 
The main purpose of this project was to increase the understanding of the renal 
filtration barrier and the role of structural glomerular proteins in the normal kidney and 
in acquired, proteinuric diseases. Increased knowledge of the mechanisms behind 
proteinuria and foot process effacement and the identification of the proteins involved, 
may sharpen our diagnostic tools in the diagnosis of kidney biopsies. The variable 
clinical appearance of many acquired glomerular diseases complicates today’s clinical 
decision-making.  The identification of specific proteins could for example serve as 
biomarkers of disease activity or progress, be used to better sub-classify glomerular 
diseases or to differentiate FSGS and MCNS. Ideally, the protein/s could be detected in 
the least invasive clinical procedure possible; in a urine sample. 
The enhanced accessibility and use of Next-generation sequencing will probably vastly 
improve the molecular identification of these diseases. This will hopefully also 
facilitate the development of more targeted therapies, in contrast to the systemically 
immune suppression currently used. 
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